AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Labcorp grew Q2 FY2026 revenue 5.8% YoY to $3,731.1M as both segments expanded operating margins — Dx +50bps to 18.0%, BLS +130bps to 17.0% — driving operating income up 14.5% to $451.6M.
Biggest Revenue Drivers
Diagnostics Laboratories (Dx)$2,900.7M+5.5% YoY
Organic revenue growth of 3.6% plus acquisitions, net of divestitures, of 1.9%; volume up 3.0% and price/mix up 2.5%
Organic growth of 6.2% and favorable FX of 1.8%, partly offset by a 1.4% drag from strategic actions in Early Development
Largest Expense Items
Cost of revenues$2,619.1M+5.6% YoY
Ratio improved to 70.2% of revenue from 70.3%, due to organic growth and operating efficiencies, partly offset by higher personnel costs
Selling, general, and administrative expenses$577.2M-0.3% YoY
Ratio improved to 15.5% of revenue from 16.4%, primarily due to revenue growth
Amortization of intangibles and other assets$78.1M+14.3% YoY
Reflects additional amortization for assets acquired subsequent to June 30, 2025
Restructuring and other charges$5.1M+21.2% YoY
Comprised of severance, facility, and contract termination costs, partly offset by reversal of unused prior liabilities
Margins: Cost of revenues fell to 70.2% of revenue from 70.3% and SG&A fell to 15.5% from 16.4%, both aided by organic revenue growth and operating efficiencies; operating income rose 14.5% YoY to $451.6M with Dx and BLS segment margins each expanding.
Watch Items from the Filing
Ravgen Inc. patent infringement verdict of $272.0M plus $100.0M enhanced damages and an ongoing per-test royalty remains under appeal by the Company.
OBBBA Medicaid/ACA changes could reduce insurance coverage and diagnostics testing utilization, though the Company currently expects no material impact.
Board increased share repurchase authorization by $1,000.0M on July 8, 2026, bringing total authorization to $1,378.6M; $451.8M repurchased in H1 2026.
AMCA data breach class action settlement (entered March 2, 2026) and Meta Pixel tracking class action settlement (entered April 2, 2026) remain subject to court approval.
Approximately 13.9% of six-month revenue is denominated in non-USD currencies (CAD, CHF, EUR, GBP); a hypothetical 10% FX move would have impacted pretax income by ~$17.1M.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Bailey Megan D.EVP, Pres, Central Labs & IntlShares withheld for tax or exercise price · Mar 26, 2026
Congress trading in LH
24 transactions in LH reported by 6 members of Congress under the STOCK Act, most recent trade Aug 25, 2026. Reported transactions, not recommendations.
About LABCORP HOLDINGS INC. (LH): stock profile, AI score and financials
LABCORP HOLDINGS INC. (LH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LH at 66.0/100 on a composite quality score built from its SEC filings, placing it at rank #440 of 2,925 stocks — the top 25% of the AI-ranked universe. LH scores in the top quartile across revenue scale (89.5), earnings quality (76.2). Based on the latest XBRL financial filings (Q2 2026), LABCORP HOLDINGS INC. reports quarterly revenue of $3.7B, net income of $298.7M, an operating margin of 12.1%. Top institutional holders of LH by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VICTORY CAPITAL MANAGEMENT, based on the most recent SEC filings. LH trades on the NYSE exchange and files with the SEC under CIK 920148. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LABCORP HOLDINGS INC. directly from SEC EDGAR.